1
|
Montaño-Rodriguez AR, Schorling T, Andressoo JO. Striatal GDNF Neurons Chemoattract RET-Positive Dopamine Axons at Seven Times Farther Distance Than Medium Spiny Neurons. Cells 2024; 13:1059. [PMID: 38920687 PMCID: PMC11202212 DOI: 10.3390/cells13121059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2024] [Revised: 06/08/2024] [Accepted: 06/12/2024] [Indexed: 06/27/2024] Open
Abstract
Glial cell line-derived neurotrophic factor (GDNF) is among the strongest dopamine neuron function- and survival-promoting factors known. Due to this reason, it has clinical relevance in dopamine disorders such as Parkinson's disease and schizophrenia. In the striatum, GDNF is exclusively expressed in interneurons, which make up only about 0.6% of striatal cells. Despite clinical significance, histological analysis of striatal GDNF system arborization and relevance to incoming dopamine axons, which bear its receptor RET, has remained enigmatic. This is mainly due to the lack of antibodies able to visualize GDNF- and RET-positive cellular processes; here, we overcome this problem by using knock-in marker alleles. We find that GDNF neurons chemoattract RET+ axons at least seven times farther in distance than medium spiny neurons (MSNs), which make up 95% of striatal neurons. Furthermore, we provide evidence that tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, is enriched towards GDNF neurons in the dopamine axons. Finally, we find that GDNF neuron arborizations occupy approximately only twelve times less striatal volume than 135 times more abundant MSNs. Collectively, our results improve our understanding of how endogenous GDNF affects striatal dopamine system function.
Collapse
Affiliation(s)
- Ana Rosa Montaño-Rodriguez
- Department of Pharmacology, Faculty of Medicine, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; (A.R.M.-R.); (T.S.)
| | - Tabea Schorling
- Department of Pharmacology, Faculty of Medicine, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; (A.R.M.-R.); (T.S.)
| | - Jaan-Olle Andressoo
- Department of Pharmacology, Faculty of Medicine, Helsinki Institute of Life Science, University of Helsinki, 00290 Helsinki, Finland; (A.R.M.-R.); (T.S.)
- Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, 17177 Stockholm, Sweden
| |
Collapse
|
2
|
Lee WL, Westergaard X, Hwu C, Hwu J, Fiala T, Lacefield C, Boltaev U, Mendieta AM, Lin L, Sonders MS, Brown KR, He K, Asher WB, Javitch JA, Sulzer D, Sames D. Molecular Design of SERTlight: A Fluorescent Serotonin Probe for Neuronal Labeling in the Brain. J Am Chem Soc 2024; 146:9564-9574. [PMID: 38557024 DOI: 10.1021/jacs.3c11617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
The serotonergic transmitter system plays fundamental roles in the nervous system in neurotransmission, synaptic plasticity, pathological processes, and therapeutic effects of antidepressants and psychedelics, as well as in the gastrointestinal and circulatory systems. We introduce a novel small molecule fluorescent agent, termed SERTlight, that specifically labels serotonergic neuronal cell bodies, dendrites, and axonal projections as a serotonin transporter (SERT) fluorescent substrate. SERTlight was developed by an iterative molecular design process, based on an aminoethyl-quinolone system, to integrate structural elements that impart SERT substrate activity, sufficient fluorescent brightness, and a broad absence of pharmacological activity, including at serotonin (5-hydroxytryptamine, 5HT) receptors, other G protein-coupled receptors (GPCRs), ion channels, and monoamine transporters. The high labeling selectivity is not achieved by high affinity binding to SERT itself but rather by a sufficient rate of SERT-mediated transport of SERTlight, resulting in accumulation of these molecules in 5HT neurons and yielding a robust and selective optical signal in the mammalian brain. SERTlight provides a stable signal, as it is not released via exocytosis nor by reverse SERT transport induced by 5HT releasers such as MDMA. SERTlight is optically, pharmacologically, and operationally orthogonal to a wide range of genetically encoded sensors, enabling multiplexed imaging. SERTlight enables labeling of distal 5HT axonal projections and simultaneous imaging of the release of endogenous 5HT using the GRAB5HT sensor, providing a new versatile molecular tool for the study of the serotonergic system.
Collapse
Affiliation(s)
- Wei-Li Lee
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Xavier Westergaard
- Department of Biological Sciences, Columbia University, New York, New York 10027, United States
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Christopher Hwu
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Jennifer Hwu
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Tomas Fiala
- Department of Chemistry, Columbia University, New York, New York 10027, United States
- Laboratory of Organic Chemistry, ETH Zürich, D-CHAB, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland
| | - Clay Lacefield
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Division of Systems Neuroscience, New York State Psychiatric Institute, New York, New York 10032, United States
| | - Umed Boltaev
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Adriana M Mendieta
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Lisa Lin
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Mark S Sonders
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States
| | - Keaon R Brown
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Keer He
- Department of Chemistry, Columbia University, New York, New York 10027, United States
| | - Wesley B Asher
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York 10032, United States
| | - Jonathan A Javitch
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York 10032, United States
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States
| | - David Sulzer
- Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, United States
- Department of Neurology, Columbia University Irving Medical Center, New York, New York 10032, United States
- Department of Molecular Pharmacology and Therapeutics, Columbia University Irving Medical Center, New York, New York 10032, United States
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York 10032, United States
| | - Dalibor Sames
- Department of Chemistry, Columbia University, New York, New York 10027, United States
- Zuckerman Mind Brain Behavior Institute, Columbia University, New York, New York 10027, United States
| |
Collapse
|
3
|
Camacho-Hernandez GA, Jahan K, Newman AH. Illuminating the monoamine transporters: Fluorescently labelled ligands to study dopamine, serotonin and norepinephrine transporters. Basic Clin Pharmacol Toxicol 2023; 133:473-484. [PMID: 36527444 DOI: 10.1111/bcpt.13827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 12/14/2022] [Accepted: 12/15/2022] [Indexed: 12/23/2022]
Abstract
Fluorescence microscopy has revolutionized the visualization of physiological processes in live-cell systems. With the recent innovations in super resolution microscopy, these events can be examined with high precision and accuracy. The development of fluorescently labelled small molecules has provided a significant advance in understanding the physiological relevance of targeted proteins that can now be visualized at the cellular level. One set of physiologically important target proteins are the monoamine transporters (MATs) that play an instrumental role in maintaining monoamine signalling homeostasis. Understanding the mechanisms underlying their regulation and dysregulation is fundamental to treating several neuropsychiatric conditions such as attention deficit hyperactivity disorder (ADHD), anxiety, depression and substance use disorders. Herein, we describe the rationale behind the small molecule design of fluorescently labelled ligands (FLL) either as MAT substrates or inhibitors as well as their applications to advance our understanding of this class of transporters in health and disease.
Collapse
Affiliation(s)
- Gisela Andrea Camacho-Hernandez
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institutes on Drug Abuse - Intramural Research Program, Baltimore, Maryland, USA
| | - Khorshada Jahan
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institutes on Drug Abuse - Intramural Research Program, Baltimore, Maryland, USA
| | - Amy Hauck Newman
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institutes on Drug Abuse - Intramural Research Program, Baltimore, Maryland, USA
| |
Collapse
|
4
|
Espallergues J, Boubaker-Vitre J, Mignon A, Avrillon M, Le Bon-Jego M, Baufreton J, Valjent E. Spatiomolecular Characterization of Dopamine D2 Receptors Cells in the Mouse External Globus Pallidus. Curr Neuropharmacol 2023; 22:CN-EPUB-133040. [PMID: 37475558 PMCID: PMC11097984 DOI: 10.2174/1570159x21666230720121027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2023] [Revised: 03/07/2023] [Accepted: 04/10/2023] [Indexed: 07/22/2023] Open
Abstract
The external globus pallidus (GPe) is part of the basal ganglia circuit and plays a key role in controlling the actions. Although, many evidence indicate that dopamine through its activation of D2 receptors (D2Rs) modulates the GPe neuronal activity, the precise spatiomolecular characterization of cell populations expressing D2Rs in the mouse GPe is still lacking. By combining single molecule in situ hybridization, cell type-specific imaging analyses, and electrophysiology slice recordings, we found that GPe D2R cells are neurons preferentially localized in the caudal portion of GPe. These neu- rons comprising pallido-striatal, pallido-nigral, and pallido-cortical neurons segregate into two distinct populations displaying molecular and electrophysiological features of GPe GABAergic PV/NKX2.1 and cholinergic neurons respectively. By clarifying the spatial molecular identity of GPe D2R neurons in the mouse, this work provides the basis for future studies aiming at disentangling the action of do- pamine within the GPe.
Collapse
Affiliation(s)
| | | | - Audrey Mignon
- IGF, University Montpellier, CNRS, Inserm, F-34094 Montpellier, France
| | - Maelle Avrillon
- IGF, University Montpellier, CNRS, Inserm, F-34094 Montpellier, France
| | | | - Jerome Baufreton
- University Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France
| | - Emmanuel Valjent
- IGF, University Montpellier, CNRS, Inserm, F-34094 Montpellier, France
| |
Collapse
|
5
|
Zheng Y, Li Y. Past, present, and future of tools for dopamine detection. Neuroscience 2023:S0306-4522(23)00295-6. [PMID: 37419404 DOI: 10.1016/j.neuroscience.2023.06.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2023] [Revised: 06/26/2023] [Accepted: 06/29/2023] [Indexed: 07/09/2023]
Abstract
Dopamine (DA) is a critical neuromodulator involved in various brain functions. To understand how DA regulates neural circuits and behaviors in the physiological and pathological conditions, it is essential to have tools that enable the direct detection of DA dynamics in vivo. Recently, genetically encoded DA sensors based on G protein-coupled receptors revolutionized this field, as it allows us to track in vivo DA dynamic with unprecedented spatial-temporal resolution, high molecular specificity, and sub-second kinetics. In this review, we first summarize traditional DA detection methods. Then we focus on the development of genetically encoded DA sensors and feature its significance to understanding dopaminergic neuromodulation across diverse behaviors and species. Finally, we present our perspectives about the future direction of the next-generation DA sensors and extend their potential applications. Overall, this review offers a comprehensive perspective on the past, present, and future of DA detection tools, with important implications for the study of DA functions in health and disease.
Collapse
Affiliation(s)
- Yu Zheng
- Peking-Tsinghua Center for Life Sciences, 100871 Beijing, China
| | - Yulong Li
- Peking-Tsinghua Center for Life Sciences, 100871 Beijing, China; State Key Laboratory of Membrane Biology, Peking University School of Life Sciences, 100871 Beijing, China; PKU-IDG/McGovern Institute for Brain Research, 100871 Beijing, China; National Biomedical Imaging Center, Peking University, 100871 Beijing, China.
| |
Collapse
|
6
|
Post MR, Sulzer D. The chemical tools for imaging dopamine release. Cell Chem Biol 2021; 28:748-764. [PMID: 33894160 PMCID: PMC8532025 DOI: 10.1016/j.chembiol.2021.04.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 02/23/2021] [Accepted: 04/06/2021] [Indexed: 02/07/2023]
Abstract
Dopamine is a modulatory neurotransmitter involved in learning, motor functions, and reward. Many neuropsychiatric disorders, including Parkinson's disease, autism, and schizophrenia, are associated with imbalances or dysfunction in the dopaminergic system. Yet, our understanding of these pervasive public health issues is limited by our ability to effectively image dopamine in humans, which has long been a goal for chemists and neuroscientists. The last two decades have witnessed the development of many molecules used to trace dopamine. We review the small molecules, nanoparticles, and protein sensors used with fluorescent microscopy/photometry, MRI, and PET that shape dopamine research today. None of these tools observe dopamine itself, but instead harness the biology of the dopamine system-its synthetic and metabolic pathways, synaptic vesicle cycle, and receptors-in elegant ways. Their advantages and weaknesses are covered here, along with recent examples and the chemistry and biology that allow them to function.
Collapse
Affiliation(s)
- Michael R Post
- Department of Psychiatry, Columbia University Medical Center, New York, NY, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA.
| | - David Sulzer
- Departments of Psychiatry, Neurology, and Pharmacology, Columbia University Medical Center, New York, NY, USA; Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA.
| |
Collapse
|
7
|
Cataldi S, Stanley AT, Miniaci MC, Sulzer D. Interpreting the role of the striatum during multiple phases of motor learning. FEBS J 2021; 289:2263-2281. [PMID: 33977645 DOI: 10.1111/febs.15908] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Revised: 03/28/2021] [Accepted: 04/30/2021] [Indexed: 01/11/2023]
Abstract
The synaptic pathways in the striatum are central to basal ganglia functions including motor control, learning and organization, action selection, acquisition of motor skills, cognitive function, and emotion. Here, we review the role of the striatum and its connections in motor learning and performance. The development of new techniques to record neuronal activity and animal models of motor disorders using neurotoxin, pharmacological, and genetic manipulations are revealing pathways that underlie motor performance and motor learning, as well as how they are altered by pathophysiological mechanisms. We discuss approaches that can be used to analyze complex motor skills, particularly in rodents, and identify specific questions central to understanding how striatal circuits mediate motor learning.
Collapse
Affiliation(s)
- Stefano Cataldi
- Departments of Psychiatry, Neurology, Pharmacology, Biology, Columbia University, New York, NY, USA.,Division of Molecular Therapeutics, New York State Psychiatric Institute, NY, USA
| | - Adrien T Stanley
- Departments of Psychiatry, Neurology, Pharmacology, Biology, Columbia University, New York, NY, USA.,Division of Molecular Therapeutics, New York State Psychiatric Institute, NY, USA
| | | | - David Sulzer
- Departments of Psychiatry, Neurology, Pharmacology, Biology, Columbia University, New York, NY, USA.,Division of Molecular Therapeutics, New York State Psychiatric Institute, NY, USA
| |
Collapse
|
8
|
He Q, Wu J, Wang X, Luo F, Yan K, Yu W, Mo Z, Jiang X. Exercise intervention can reduce the degree of drug dependence of patients with amphetamines/addiction by improving dopamine level and immunity and reducing negative emotions. Am J Transl Res 2021; 13:1779-1788. [PMID: 33841702 PMCID: PMC8014419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Accepted: 08/26/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVE Exercise intervention can reduce drug dependence of patients with amphetamines addiction by improving dopamine level and immunity, and reducing negative emotions. METHODS Altogether 90 male patients with amphetamines addiction from March 2018 to June 2019 were selected and grouped. The routine rehabilitation group (RG) (30 cases) was given conventional rehabilitation treatment, while group 1 (30 cases) was given conventional rehabilitation treatment+aerobic exercise for 1 hour. Group 2 (30 cases) received routine rehabilitation+aerobic exercise+strength training for 1 hour. Before and after exercise intervention, the three groups were tested for psychological state with self-rating depression scale (SDS). Visual analogue scale (VAS) was used to evaluate the drug craving. Positive and negative syndrome scale (PANSS) and quality of life scale for drug addiction (QOL-DA) were used to detect the mental status and QOL. The immune function, high sensitivity C-reactive protein (hs-CRP) and dopamine (DA) levels were detected. RESULTS After intervention, the SDS, VAS and PANSS of group 1 and group 2 weresignificantly better than those of RG, while the improvement of scores of group 2 wassignificantly better than that of group 1 (P < 0.05). hs-CRP in group 1 and group 2 were significantly lower than those in RG, while hs-CRP in group 2 weresignificantly lower than those in group 1 (P < 0.05). IgA, IgG and DA in group 1 and group 2 weresignificantly higher than those in RG, and IgA, IgG and DA in group 2 weresignificantly higher than those in group 1 (P < 0.05). QOL-DA in group 1 and 2 weresignificantly higher than those of RG, and the improvement of scores of group 2 wassignificantly better than that of group 1 (P < 0.05). CONCLUSION Psychological status, drug craving, immune function, DA and QOL of patients with amphetamines addiction have been improved after exercise intervention.
Collapse
Affiliation(s)
- Qinghua He
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Jingqiong Wu
- Department of Physical Education, Guangxi Medical UniversityNanning 530021, Guangxi, China
| | - Xin Wang
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Fuxuan Luo
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Kaihui Yan
- The Sixth Compulsory Isolation and Rehabilitation Center of GuangxiBeihai 536000, Guangxi Province, China
| | - Wenjun Yu
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Zaimei Mo
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| | - Xinping Jiang
- School of Physical Education and Health Science, Guangxi University for NationalitiesNanning 530006, Guangxi, China
| |
Collapse
|
9
|
Sabatini BL, Tian L. Imaging Neurotransmitter and Neuromodulator Dynamics In Vivo with Genetically Encoded Indicators. Neuron 2020; 108:17-32. [PMID: 33058762 DOI: 10.1016/j.neuron.2020.09.036] [Citation(s) in RCA: 98] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2020] [Revised: 08/10/2020] [Accepted: 09/25/2020] [Indexed: 12/16/2022]
Abstract
The actions of neuromodulation are thought to mediate the ability of the mammalian brain to dynamically adjust its functional state in response to changes in the environment. Altered neurotransmitter (NT) and neuromodulator (NM) signaling is central to the pathogenesis or treatment of many human neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, depression, and addiction. To reveal the precise mechanisms by which these neurochemicals regulate healthy and diseased neural circuitry, one needs to measure their spatiotemporal dynamics in the living brain with great precision. Here, we discuss recent development, optimization, and applications of optical approaches to measure the spatial and temporal profiles of NT and NM release in the brain using genetically encoded sensors for in vivo studies.
Collapse
Affiliation(s)
- Bernardo L Sabatini
- Howard Hughes Medical Institute, Department of Neurobiology, Harvard Medical School, Boston, MA, USA.
| | - Lin Tian
- Departments of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, Davis, CA, USA.
| |
Collapse
|
10
|
Guille-Collignon M, Lemaître F. Overview and outlook of the strategies devoted to electrofluorescence surveys: Application to single cell secretion analysis. Trends Analyt Chem 2020. [DOI: 10.1016/j.trac.2020.116055] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
11
|
Labouesse MA, Cola RB, Patriarchi T. GPCR-Based Dopamine Sensors-A Detailed Guide to Inform Sensor Choice for In vivo Imaging. Int J Mol Sci 2020; 21:E8048. [PMID: 33126757 PMCID: PMC7672611 DOI: 10.3390/ijms21218048] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2020] [Revised: 09/25/2020] [Accepted: 09/26/2020] [Indexed: 12/12/2022] Open
Abstract
Understanding how dopamine (DA) encodes behavior depends on technologies that can reliably monitor DA release in freely-behaving animals. Recently, red and green genetically encoded sensors for DA (dLight, GRAB-DA) were developed and now provide the ability to track release dynamics at a subsecond resolution, with submicromolar affinity and high molecular specificity. Combined with rapid developments in in vivo imaging, these sensors have the potential to transform the field of DA sensing and DA-based drug discovery. When implementing these tools in the laboratory, it is important to consider there is not a 'one-size-fits-all' sensor. Sensor properties, most importantly their affinity and dynamic range, must be carefully chosen to match local DA levels. Molecular specificity, sensor kinetics, spectral properties, brightness, sensor scaffold and pharmacology can further influence sensor choice depending on the experimental question. In this review, we use DA as an example; we briefly summarize old and new techniques to monitor DA release, including DA biosensors. We then outline a map of DA heterogeneity across the brain and provide a guide for optimal sensor choice and implementation based on local DA levels and other experimental parameters. Altogether this review should act as a tool to guide DA sensor choice for end-users.
Collapse
Affiliation(s)
- Marie A. Labouesse
- Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA;
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY 10032, USA
| | - Reto B. Cola
- Anatomy and Program in Neuroscience, University of Fribourg, 1700 Fribourg, Switzerland;
- Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland
| | - Tommaso Patriarchi
- Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland
- Neuroscience Center Zurich, University and ETH Zurich, 8057 Zurich, Switzerland
| |
Collapse
|
12
|
Rahman N, Mihalkovic A, Geary O, Haffey R, Hamilton J, Thanos PK. Chronic aerobic exercise: Autoradiographic assessment of GABA(a) and mu-opioid receptor binding in adult rats. Pharmacol Biochem Behav 2020; 196:172980. [PMID: 32593790 DOI: 10.1016/j.pbb.2020.172980] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Revised: 06/19/2020] [Accepted: 06/24/2020] [Indexed: 12/21/2022]
Abstract
Exercise programs have shown great potential for both the prevention and treatment of substance use disorder (SUD). As exercise has been shown to have potent effects on physical and psychological health, it is reasonable to examine the mechanism of how exercise can be used as an adjunct treatment for addiction. The present study examined the effects of chronic aerobic (treadmill) exercise on both GABA(a) and mu-opioid receptor levels in the brains of male and female rats. GABA(a) receptor binding, measured by [3H] Flunitrazepam, was increased in the cingulate cortex following exercise, but only in females. Mu-opioid receptor expression, measured by [3H] ([D-Ala2, N-MePhe4, Gly-ol]-enkephalin) (DAMGO), showed no effect of exercise while showing an effect of sex, with increased [3H] DAMGO binding in the brains of sedentary males compared to that of sedentary females. Our findings support the potential role for GABA(a) signaling in the cingulate cortex as part of the mechanism of action of aerobic exercise. These data, along with prior reports, aid our understanding of the neurochemical impact and mechanism of chronic aerobic exercise on neuropsychiatric disease, particularly regarding addiction.
Collapse
Affiliation(s)
- Nabeel Rahman
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America
| | - Abrianna Mihalkovic
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America; Department of Psychology, University at Buffalo, Buffalo, NY 14203, United States of America
| | - Olivia Geary
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America
| | - Rylee Haffey
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America
| | - John Hamilton
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America; Department of Psychology, University at Buffalo, Buffalo, NY 14203, United States of America
| | - Panayotis K Thanos
- Behavioral Neuropharmacology and Neuroimaging Laboratory on Addictions (BNNLA), Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY 14203, United States of America; Department of Psychology, University at Buffalo, Buffalo, NY 14203, United States of America.
| |
Collapse
|
13
|
Cellular and Synaptic Dysfunctions in Parkinson's Disease: Stepping out of the Striatum. Cells 2019; 8:cells8091005. [PMID: 31470672 PMCID: PMC6769933 DOI: 10.3390/cells8091005] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 08/28/2019] [Accepted: 08/29/2019] [Indexed: 12/30/2022] Open
Abstract
The basal ganglia (BG) are a collection of interconnected subcortical nuclei that participate in a great variety of functions, ranging from motor programming and execution to procedural learning, cognition, and emotions. This network is also the region primarily affected by the degeneration of midbrain dopaminergic neurons localized in the substantia nigra pars compacta (SNc). This degeneration causes cellular and synaptic dysfunctions in the BG network, which are responsible for the appearance of the motor symptoms of Parkinson’s disease. Dopamine (DA) modulation and the consequences of its loss on the striatal microcircuit have been extensively studied, and because of the discrete nature of DA innervation of other BG nuclei, its action outside the striatum has been considered negligible. However, there is a growing body of evidence supporting functional extrastriatal DA modulation of both cellular excitability and synaptic transmission. In this review, the functional relevance of DA modulation outside the striatum in both normal and pathological conditions will be discussed.
Collapse
|